MRVIHIGH SIGNALFINANCIAL10-K

MRVI experienced severe financial deterioration with operating cash flow turning negative at -$57.6M and gross profit margins collapsing 68.6% despite only a 28.3% revenue decline.

The disproportionate decline in gross profit relative to revenue suggests significant margin compression or operational inefficiencies that management may be struggling to control. The swing from positive to deeply negative operating cash flow combined with substantial asset base shrinkage indicates potential liquidity stress and operational challenges that could threaten the company's financial stability.

Comparing 2026-02-26 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

MRVI's financial performance deteriorated dramatically across all major metrics, with revenue declining 28.3% to $185.7M while gross profit collapsed 68.6% to just $34.0M, indicating severe margin compression. Operating cash flow swung from positive $7.5M to negative $57.6M, while the company's asset base contracted significantly with total assets falling 23.6% and cash reserves dropping 32.7% to $216.9M. The combination of operational losses, negative cash generation, and shrinking balance sheet suggests fundamental business challenges that extend beyond normal cyclical pressures.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-871.2%
$7.5M-$57.6M

Operating cash flow fell 871.2% — earnings quality concerns; investigate working capital changes and non-cash items.

Interest Expense
P&L
+124.8%
$20.4M$45.9M

Interest expense surged 124.8% — significant debt increase or rising rates materially impacting earnings.

Gross Profit
P&L
-68.6%
$108.3M$34.0M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Capital Expenditure
Cash Flow
-55.7%
$29.7M$13.1M

Capex reduced 55.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-34.7%
$325.3M$212.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Accounts Receivable
Balance Sheet
-33.8%
$38.5M$25.5M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Cash & Equivalents
Balance Sheet
-32.7%
$322.4M$216.9M

Cash declined 32.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-31%
$429.1M$296.3M

Current assets declined 31% — monitor working capital adequacy and short-term liquidity.

Revenue
P&L
-28.3%
$259.2M$185.7M

Revenue softened 28.3% — monitor whether this is cyclical or structural.

Total Assets
Balance Sheet
-23.6%
$1.0B$770.6M

Total assets contracted 23.6% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-18
ADDED
As of February 19, 2026, 146,383,162 shares of the registrant s Class A common stock were outstanding and 110,684,080 shares of the registrant s Class B common stock were outstanding.
(also referred to in this document as Maravai, we, us, our or the Company ) is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease.
Our customers include biopharmaceutical companies, emerging biotech firms, life science research organizations, academic research institutions and diagnostics companies.
Business Segments and Products We operate and report our business in two segments TriLink, formerly referred to as Nucleic Acid Production, and Cygnus, formerly referred to as Biologics Safety Testing.
During fiscal year 2025, we renamed our reportable segments from Nucleic Acid Production and Biologics Safety Testing to TriLink and Cygnus, respectively.
+7 more — sign up free →
REMOVED
As of March 11, 2025, 143,651,803 shares of the registrant s Class A common stock were outstanding and 110,684,080 shares of the registrant s Class B common stock were outstanding.
(also referred to in this document as Maravai, we, us, our or the Company ) is a leading life sciences company dedicated to providing critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics.
Our solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization.
We proudly serve a diverse global customer base, including the world s top biopharmaceutical companies ranked by research and development investment, emerging biotech firms, renowned academic research institutions and leading in vitro diagnostics companies.
At Maravai, we are committed to supporting our customers throughout their journey from early discovery to commercialization helping bring life-changing innovations to patients worldwide.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →